Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2001, p. 1810-1814, Vol. 45, No. 6
Queensland Institute of Medical Research,
Brisbane, Queensland 4029, Australia
Received 2 November 2000/Returned for modification 21 December
2000/Accepted 19 March 2001
A simple technique for routine, reproducible global surveillance of
the drug susceptibility status of the anaerobic protozoa Trichomonas, Entamoeba, and Giardia is
described. Data collected using this technique can be readily compared
among different laboratories and with previously reported data. The
technique employs a commercially available sachet and bag system to
generate a low-oxygen environment and log2 drug dilutions
in microtiter plates, which can be monitored without aerobic exposure,
to assay drug-resistant laboratory lines and clinically resistant
isolates. MICs (after 2 days) of 3.2 and 25 µM indicated
metronidazole-sensitive and highly clinically resistant isolates of
T. vaginalis in anaerobic assays, respectively. The aerobic
MICs were 25 and >200 µM. MICs (1 day) of 12.5 to 25 µM were found
for axenic lines of E. histolytica, and MICs for G. duodenalis (3 days) ranged from 6.3 µM for
metronidazole-sensitive isolates to 50 µM for laboratory
metronidazole-resistant lines. This technique should encourage more
extensive monitoring of drug resistance in these organisms.
One of the most important issues for
future biomedical research is the development of antimicrobial
resistance and the lack of coordinated multinational surveillance
mechanisms (25). Overuse and abuse, inappropriate
treatment regimens, and over-the-counter sales of cheap and effective
drugs in many parts of the world have already rendered chloroquine,
penicillin, and methicillin ineffective against Plasmodium
falciparum, Streptococcus pneumoniae, and Staphylococcus
aureus, respectively (17, 44).
Infections by the anaerobic protozoa Trichomonas vaginalis,
Giardia duodenalis, and Entamoeba histolytica are
treated with metronidazole (Flagyl) or one of the related
5-nitroimidazole family of drugs such as tinidazole (Fasigyn) (1,
21, 31, 40). Metronidazole is the only drug approved for the
treatment of trichomoniasis in some countries, the only safe treatment
for invasive amoebiasis, and the favored treatment for giardiasis (40). It is cheap, easy to produce, safe, and effective;
as a result, it is widely prescribed for a host of ailments including the treatment of infections by anaerobic bacteria including
Helicobacter pylori (13), for prophylaxis, and
postoperatively (39, 40). It is sold over the counter in
many Asian countries, where optimal courses of treatment are rarely
recommended or taken (43). Albendazole (Zentel) is an
alternative for the treatment of giardiasis, with 62 to 95% reported
efficacy compared with 97% for metronidazole (16).
Trichomonal infection of women ranges from an asymptomatic carrier
state to profound, acute, inflammatory disease (28). Infections have been linked to sterility problems, low birth weight, and preterm delivery (30). These in turn are closely
associated with high infant mortality. It is now generally accepted
that T. vaginalis infection predisposes carriers to human
immunodeficiency virus (HIV) and AIDS (8, 9) and cervical
cancer (41). Given the prevalence of T. vaginalis, and consequent attributable risk to HIV transmission,
screening for and treatment of Trichomonas could prove to be
the single most cost-effective step in HIV incidence reduction
(4). Giardiasis is a significant gut pathogen causing acute and chronic diarrhea and failure to thrive in children
(12). In Mexico alone, approximately 10% of the
population has had an episode of invasive amoebiasis and a significant
number will succumb to amoebic abscesses (7).
Drug failures in trichomoniasis treatment appeared soon after
metronidazole was introduced in the 1960s (40; see
reference 24 for references), and there has been an
alarming increase in recent years (32). Resistance has
recently been confirmed among clinical isolates of Giardia
via difficult in vivo assays (22). In a concerted effort
to sustain the usefulness of this very valuable drug, uniform assays
for the assessment of its susceptibility in anaerobic assays need to be
established for current as well as future worldwide comparisons.
In the past, susceptibility assays have been monitored for a variety of
end points and reported as 50% inhibitory concentrations (IC50) for Giardia ranging from 0.01 to 1 µg/ml, 50% inhibitory dose (ID50) values of 0.2 and 1.5 µg/ml for Giardia (see reference 39 for
references), minimum lethal concentrations (MLCs) after 72 h of 50 to 100 µM for susceptible organisms (36) and 11.6 µM
for the HM-1 strain of E. histolytica (6), and
on MIC of >15 µg/ml indicating resistance in anaerobic assays after
48 h (24). The assortment of assays found in the
literature prevents comparison of data among different laboratories. In
some cases the method of assay is not detailed, often as a result of
shortage of journal space, and the experiment is therefore
irreproducible (42).
Traditionally two major choices for susceptibility assays have been
available: tube assays and microtiter plate assays. Microtiter plates
are problematic due to the variability of the anaerobic environment and
the need to remove the plates from the anaerobic or low-oxygen
environment to monitor the progress of the assay. Tube assays are too
cumbersome and time-consuming, with few if any replicates possible. A
variety of methods have been used to generate a low-oxygen environment,
including nitrogen flushing of parasites in 96-well plates
(2), oxygen regulation of trichomonads in 24-well plates
within anaerobic jars (24), and tube assays containing an
oxygen-depleting medium (15). The aim of this study is to
describe a simplified new method which may be extensively used for the
determination of chemosensitivity in the anaerobic protozoa. The new
method uses the Anaerocult C minisystem (Merck) for
Trichomonas and Giardia and the Anaerocult A
system (Merck) for Entamoeba. The Anaerocult C mini-system
generates a 9% CO2-6% O2 atmosphere after
24 h (manufacturer's data sheet), while the Anaerocult A system
generates 18% CO2-<0.1% O2 within 150 min when used as recommended in an anaerobic jar (manufacturer's data sheet). The microtiter plates are sealed in special incubation bags
provided with the Anaerocult C minisystem together with the sachet
which creates the low-oxygen environment. The plates can be monitored
while sealed within the bags over several days and are incubated in a
nongassed 37°C incubator. Parasites are monitored for viability, and
in our experience drug MICs obtained using log2 drug
dilutions provide clear results.
For methods to be standardized worldwide, equipment must be kept
to a minimum. The following assays require the use of flat-bottom, sterile, tissue culture microtiter plates, a multichannel pipettor, an
incubator, and an inverted microscope. The low-oxygen environment is
generated using the Anaerocult C minisystem, which comes with special
incubation bags in which to seal the microtiter plates. The bags can be
sealed with an Anaeroclip (Merck) or a plastic bag sealer. The
Anaerocult A system was designed for an anaerobic jar, but we cut one
small square from the large (four by two squares) sachet and use it in
the same way as the Anaerocult C minisystem for Entamoeba assays.
Parasite culture and isolates.
All parasites were grown in
TYI-S-33 (10), which was supplemented with bile for
Giardia assays (19). The parasites were subcultured three times a week, except for Entamoeba, which
was subcultured twice a week. Parasites to be used in drug
susceptibility assays were grown for 1 day following regular
subculturing and were in the log phase of growth. Drug-resistant lines
were grown without drug for this period.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.6.1810-1814.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Drug Susceptibility Testing of Anaerobic
Protozoa
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Drug susceptibility assays.
Stock solutions (0.1 M) of drug
(17.1 mg/ml for metronidazole; 26.5 mg/ml for albendazole [Sigma]) in
N,N-dimethylformamide (DMF; high-pressure liquid
chromatography grade [Sigma]) or dimethyl sulfoxide (Sigma) were
prepared and stored at
20°C. The stock solution was diluted in
medium to the required concentration. A useful starting concentration
was 200 µM, which yields a maximum concentration in the assay of 100 µM (17.1 µg of metronidazole per ml and 26.5 µg of albendazole
per ml). In aerobic Trichomonas assays, a maximum
concentration of at least 200 µM in the wells is recommended. A
similar dilution of DMF or dimethyl sulfoxide was prepared for control
wells. A 200-µl volume of diluted drug was added to wells 1, 3, 4, 6, etc., of row A, and 200 µl of diluted DMF was added to wells 2, 5, etc., of a 96-well flat-bottom, covered tissue culture plate (Costar).
A 100-µl volume of medium was added to all other wells. Double
dilutions down the plate were performed, and the last 100 µl from
each well of row H was discarded. A 100-µl volume of medium
containing parasites of the first strain was added to wells in columns
1, 2, 3, 4, 5, and 6. Parasites of a second strain were added to wells
in columns 7, 8, 9, 10, 11, and 12. Final drug concentrations in rows A
to H were typically 100, 50, 25, 12.5, 6.3, 3.2, 1.6, and 0.8 µM,
respectively (17, 8.5, 4.25, 2.12, 1.06, 0.52, 0.26, and 0.13 µg of
metronidazole per ml). For each strain and drug concentration, there
were four replicates with drug and two without. If other drugs are to
be compared with metronidazole, the replicates and plate arrangement can be adjusted. However, it is important to ensure sufficient replicated wells to avoid edge effects for both control and
drug-containing wells (a minimum of three wells for each concentration
of drug for each strain is suggested).
| |
RESULTS |
|---|
|
|
|---|
T. vaginalis. (i) Anaerobic assays.
After 1 day
small numbers of parasites were scored, but by 2 days the control wells
were at least 3+. By 3 days the fast-growing drug-sensitive isolates in
the control wells were overgrown while the drug-resistant lines were
4+. Trophozoites growing in 0.8 µM metronidazole were either 3+ or
4+. The MIC of metronidazole for F1623, which is regarded as a
susceptible isolate, was the lowest, at 3.2 µM (most frequently
obtained value, the mode) with a range of 1.6 to 6.25 µM (Table
1). The previously uncharacterized drug-susceptible isolate 11147 was intermediate between the susceptible isolate and the clinically resistant isolate, for which the minimum MIC
was 25 µM. The MIC for laboratory-induced metronidazole-resistant line F1623-M1 was >100 µM (mode) (Table 1). A second worker who carried out assays with T. vaginalis obtained a MIC mode of
1.6 µM for F1623 (12 attempts, 83% frequency, 1.6 to 3.2 range) and a MIC mode of 50 µM for F1623-M1 (3 attempts, 66% frequency, 50 to
200 range). Differences between the data presented in Table 1 and the
above data may be a result of plate scoring. Nevertheless, the MICs for
F1623 were in the 1.6 to 6.3 µM range, the drug-sensitive range, and
MICs for F1623-M1 were clearly within the clinically resistant range.
|
(ii) Aerobic assays. The results of the aerobic assays confirmed the ranking of the metronidazole susceptibility of the isolates observed in the anaerobic assays. The highly metronidazole-resistant line F1623-M1 did not grow under aerobic conditions (Table 1).
E. histolytica. The assays were more reliable when the Anaerocult A rather than the Anaerocult C system was used and were best read after 24 h. There was no apparent difference in the mode (Table 1) of these assays between the line HM1-M1 and its parent strain. However, at least one assay of HM1-M1 indicated increased resistance (Table 1). MUTM-M1 was consistently at least twofold less susceptible to metronidazole than was the parent strain, MUTM, in the same assay (Table 1).
G. duodenalis. The MIC for metronidazole-susceptible lines was 6.3 µM (mode) in these assays, and that for the resistant lines was consistently higher (Table 1). Although the concentration of metronidazole in which 106-2ID10 is maintained is low, the strain can survive higher concentration of drug. The albendazole-resistant line WB-M3-Alb, which was derived from the metronidazole-resistant line WB-M3, has apparently lost its resistance to metronidazole but is less susceptible to albendazole than its parent strain. The reportedly high in vitro susceptibility of Giardia isolates to albendazole in comparison with metronidazole (11) was evident (Table 1).
| |
DISCUSSION |
|---|
|
|
|---|
One of the difficult aspects of anaerobic drug susceptibility assays is standardization of the low-oxygen environment. The Anaerocult systems allow the environment to be duplicated from experiment to experiment and from laboratory to laboratory. They allow the use of multiwell plates, thus removing the tedium and unreliable reproducibility of tube assays. These systems provide the scientific community, including diagnosticians, with a uniform method of carrying out anaerobic drug susceptibility assays of the anaerobic protozoa so that data for clinical isolates can be compared both worldwide and with future data.
More complex and sophisticated drug susceptibility assays than those described here, with more precise readouts, have been reported, but these may be difficult to reproduce in some laboratories. For example, [3H]thymidine uptake (2) has been used to estimated ID50s, but the cost and accessibility of radioactive compounds and associated equipment in some parts of the world are prohibitive. Similarly, Kang et al. (18) and Gero et al. (14) developed antigiardial and antitrichomonal activity colorimetric assays which employ synthetic substrates of purine salvage pathway enzymes and require an enzyme-linked immunosorbent assay reader. Although Meri et al. (24) reported the use of the Anaerocult A system to create an anaerobic environment in jars, the bag system that we used will provide a more reproducible, low-cost assay. Our assays have been used successfully to assess clinical isolates in Durban, South Africa (unpublished data), and are being used in India to establish E. histolytica assays for clinical isolates growing xenically. Clearly, the assay using axenic lines will have to be adapted to xenic cultures, since axenic cultures of E. histolytica are notoriously difficult to establish.
Future considerations include assay of clinical metronidazole-resistant Giardia isolates such as those described by Lemée et al. (22) and identification of stable clinical metronidazole-resistant Entamoeba strains. These stable drug-resistant isolates, together with clinically resistant T. vaginalis strains, some of which are well characterized in the literature (27, 42), can be deposited or identified in the American Type Culture Collection protist bank as a source of positive control strains that can be used as standards along with laboratory-induced drug-resistant strains.
The number of trophozoites used in the assays is adjusted to provide a useful reading after a specified time. For T. vaginalis, 5 × 103 trophozoites per well gave a reliable reading after 48 h; for E. histolytica, approximately 1 × 104 in 24 h was successful, and for G. duodenalis, 4 × 104 was reliable after 72 h. Fewer trichomonads were required because of their rapid growth in comparison with Giardia, while the size of the E. histolytica trophozoite in comparison with either Giardia or Trichomonas was the reason for its relatively low number. Two- to threefold-lower numbers of trophozoites did not alter the MIC.
It is important to report the MIC as a molar concentration to standardize the comparison of efficacy between different drugs, especially if, for example, metronidazole is being compared with another nitroimidazole with a significantly higher molecular weight.
The MICs reported for metronidazole-resistant lines in the three different species used do not necessarily correlate with the amount of metronidazole in which the so-called resistant lines grow. This emphasizes the need to rigorously report assay readouts over an established period. The MIC for E. histolytica in our assays suggests that the parent strains could survive in approximately 10 µM metronidazole. This is not the case for long periods, and continued exposure to fresh supplies of drug, as indicated in our previous work (29), where the resistant line MUTM-M1 survived in 10 µM metronidazole but the parent isolate did not, will result in death of the culture. It is possible, however, to induce levels of resistance in E. histolytica with parasites maintained in 40 µM metronidazole (45).
The high level of metronidazole resistance reached by trichomonads (5, 20) reflects the ability of the parasite to down-regulate all hydrogenosomal function, thus circumventing metronidazole activation, and to use alternative metabolic pathways (5). Aerobic versus anaerobic resistance in Trichomonas isolates is an important consideration since most reports indicate no apparent anaerobic resistance but significant levels of aerobic resistance (26, 27). The highly metronidazole-resistant laboratory line, F1623-M1, for which the MIC mode is >100 µM metronidazole, was unable to grow aerobically, as documented for other resistant trichomonads (26). An anaerobic MIC of 25 µM after 48 h for T. vaginalis isolate B7268 provides a MIC for clinical resistance associated with great difficulty in patient treatment. MICs of 6.3 µM or less appear to correlate with 5-nitroimidazole susceptibility.
Lemée et al. (22) correlated clinical resistance to a standard antigiardial therapy with ID50s of 125, 175, and 149 mg of metronidazole per kg assayed in a mouse model. Treatment efficacy correlated with a range of ID50s from 31 to 81 mg/kg. Thus, an apparently two- to threefold increase in resistance of the parasite grown in mice is sufficient to indicate clinical resistance and treatment failures. A threefold decrease in the activity of the enzyme pyruvate:ferredoxin oxidoreductase (35) and a twofold decrease in ferredoxin activity (23) in the metronidazole-resistant laboratory line WB-M3 may therefore be sufficient for clinical resistance. Similarly, a three- to fivefold increase in MRP activity renders tumor cells resistant to chemotherapy (46). The reason for using the mouse model for the assays (22) is the difficulty in establishing in vitro cultures of G. duodenalis, with the best success rates reporting around 50% of samples finally established in culture (38).
The 50 µM MIC for the metronidazole-resistant line WB-M3, which is maintained in 58 µM metronidazole, reflects the differences in growth conditions in tubes versus the conditions in the microtiter plate in the Anaerocult C anaerobic environment and emphasizes the importance of using consistent and reproducible assay conditions for drug susceptibility assays. Conversely, the MIC for 106-2ID10, which is grown in 5 µM metronidazole, is 25 µM in the assay. We have not previously reported the decreased metronidazole resistance following long-term growth in the absence of metronidazole in the line WB-M3, as was evident in WB-M3-Alb. WB-M3 was selected from surviving trophozoites exposed to high levels of metronidazole following UV mutagenesis (34) and was one of the most successful survivors when exposed long-term to albendazole (37). WB-M3 maintains its resistance characteristics for several days without the drug but has not been tested for sensitivity after months or years in the absence of metronidazole, similarly to WB-M3-Alb. The line 106-2ID10, which was induced to be metronidazole resistant following exposure to low levels of drug, reverted to sensitivity after 22 weeks without drug the (3).
This simple assay system provides a realistic common reference assay and is the first step toward global surveillance of the development of drug resistance in the anaerobic protozoa. It can be used in any basic laboratory equipped with an incubator and sterile culture facilities and allows comparisons of the more sophisticated methods for their interpretation of aerobic and anaerobic resistance among different isolates and for their correlation with earlier techniques.
| |
ACKNOWLEDGMENTS |
|---|
We thank Ray Campbell for his technical expertise and for maintaining parasite cultures, and we thank Linda Dunn for consultation and advice. We also thank Nirma Samarawickrema for establishing lines of metronidazole-resistant E. histolytica.
This work is supported in part by the National Health and Medical Research Council of Australia.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia. Phone: 61 7 3362 0369. Fax: 61 7 3362 0105. E-mail: jacquiU{at}qimr.edu.au.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Boreham, P. F. L. 1991. Giardiasis and its control. Pharm. J. 234:271-274. |
| 2. |
Boreham, P. F. L.,
R. E. Phillips, and R. W. Shepherd.
1984.
The sensitivity of Giardia intestinalis to drugs in vitro.
J. Antimicrob. Chemother.
14:449-461 |
| 3. | Boreham, P. F. L., R. E. Phillips, and R. W. Shepherd. 1988. Altered uptake of metronidazole in vitro by stocks of Giardai intestinalis with different drug sensitivities. Trans. R. Soc. Trop. Med. Hyg. 82:104-106[CrossRef][Medline]. |
| 4. | Bowden, F. J., and G. P. Garnett. 1999. Why is Trichomonas vaginalis ignored? Sex. Transm. Infect. 75:372-373[Medline]. |
| 5. | Brown, D. M., J. A. Upcroft, H. N. Dodd, N. Chen, and P. Upcroft. 1999. Alternative 2-keto acid oxidoreductase activities in Trichomonas vaginalis. Mol. Biochem. Parasitol. 98:203-214[CrossRef][Medline]. |
| 6. | Burchard, G. D., and D. Mirelman. 1988. Entamoeba histolytica: virulence potential and sensitivity to metronidazole and emetine of four isolates possessing nonpathogenic zymodemes. Exp. Parasitol. 66:231-242[CrossRef][Medline]. |
| 7. | Caballero-Salcedo, A., M. Viveros-Rogel, B. Salvatierra, R. Tapia-Conyer, J. Sepulveda-Amor, G. Gutierrez, and L. Ortiz-Ortiz. 1994. Seroepidemiology of amebiasis in Mexico. Am. J. Trop. Med. Hyg. 4:412-419. |
| 8. |
Cohen, J.
2000.
HIV transmission AIDS researchers look to Africa for new insights.
Science
287:942 |
| 9. | Cohen, M. S. 1998. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 351(Suppl. 3):5-7[CrossRef][Medline]. |
| 10. | Diamond, L. S., D. Harow, and C. C. Cunnick. 1978. A new medium for the axenic cultivation of Entamoeba histolytica and other Entamoeba. Trans. R. Soc. Trop. Med. Hyg. 72:431-432[CrossRef][Medline]. |
| 11. | Edlind, T. D., T. L. Hang, and P. R. Chakraborty. 1990. Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro. J. Infect. Dis. 162:1408-1411[Medline]. |
| 12. | Farthing, M. J. G. 1993. Diarrhoeal disease: current concepts and future challenges. Pathogenesis of giardiasis. Trans. R. Soc. Trop. Med. Hyg. 87:17-21. |
| 13. | Freeman, C. D., N. E. Klutman, and K. C. Lamp. 1997. Metronidazole. A therapeutic review and update. Drugs 54:679-708[Medline]. |
| 14. | Gero, A. M., E. W. Kang, J. E. Harvey, P. J. Schofield, K. Clinch, and R. H. Furneaux. 2000. Trichomonas vaginalis: detection of nucleoside hydrolase activity as a potential screening procedure. Exp. Parasitol. 94:125-128[CrossRef][Medline]. |
| 15. | Gillin, F. D. 1984. The role of reducing agents and the physiology of trophozoite attachment, p. 111-130. In S. L. Erlandsen, and E. A. Meyer (ed.), Giardia and giardiasis. Plenum Press, New York, N.Y. |
| 16. | Hall, A., and Q. Nahar. 1993. Albendazole as a treatment for infections with Giardia duodenalis in children in Bangladesh. Trans. R. Soc. Trop. Med. Hyg. 87:84-86[CrossRef][Medline]. |
| 17. | Hand, W. L. 2000. Current challenges in antibiotic resistance. Adolesc. Med. 11:427-438[Medline]. |
| 18. | Kang, E. W., K. Clinch, R. H. Furneaux, J. E. Harvey, P. J. Schofield, and A. Gero. 1998. A novel and simple colorimetric method for screening Giardia intestinalis and anti-giardial activity in vitro. Parasitology 117:229-234. |
| 19. | Keister, D. B. 1983. Axenic culture of Giardia lamblia in TYI-S-33 medium supplemented with bile. Trans. R. Soc. Trop. Med. Hyg. 77:487-488[CrossRef][Medline]. |
| 20. | Kulda, J., J. Tachezy, and A. Erkasovová. 1993. In vitro induced anaerobic resistance to metronidazole in Trichomonas vaginalis. J. Eukaryot. Microbiol. 40:262-269[Medline]. |
| 21. | Lau, A. H., N. P. Lam, S. C. Piscitelli, L. Wilkes, and L. H. Danziger. 1992. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin. Pharmacokinet. 23:328-364[Medline]. |
| 22. |
Lemée, V.,
I. Zaharia,
G. Nevez,
M. Rabodonirina,
P. Brasseur,
J. J. Ballet, and L. Favennec.
2000.
Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France.
J. Antimicrob. Chemother.
46:819-821 |
| 23. | Liu, S. M., D. M. Brown, P. O'Donoghue, P. Upcroft, and J. A. Upcroft. 2000. Ferredoxin involvement in metronidazole resistance of Giardia duodenalis. Mol. Biochem. Parasitol. 108:137-140[CrossRef][Medline]. |
| 24. |
Meri, T.,
T. S. Jokiranta,
L. Suhonen, and S. Meri.
2000.
Resistance of Trichomonas vaginalis to metronidazole: report of the first three cases from Finland and optimization of in vitro susceptibility testing under various oxygen concentrations.
J. Clin. Microbiol.
38:763-767 |
| 25. | Monet, D. L. 2000. Toward multinational antimicrobial resistance surveillance systems in Europe. Int. J. Antimicrob. Agents 15:91-101[CrossRef][Medline]. |
| 26. | Müller, M. 1990. Biochemistry of Trichomonas vaginalis, p. 53-83. In B. M. Honigberg (ed.), Trichomonads parasite in humans. Springer-Verlag, New York, N.Y. |
| 27. |
Müller, M., and T. E. Gorrell.
1983.
Metabolism and metronidazole uptake in Trichomonas vaginalis isolates with different metronidazole susceptibilities.
Antimicrob. Agents Chemother.
24:667-673 |
| 28. | Rein, M. F., and M. Müller. 1990. Trichomonas vaginalis and trichomoniasis, p. 481-492. In K. K. Holmes, P.-A. Mårdh, P. F. Sparling, and P. J. Wiesner (ed.), Sexually transmitted diseases. McGraw-Hill Book Co., New York, N.Y. |
| 29. |
Samarawickrema, N. A.,
D. M. Brown,
J. A. Upcroft,
N. Thammapalerd, and P. Upcroft.
1997.
Involvement of superoxide dismutase and pyruvate: ferredoxin oxidoreductase in mechanisms of metronidazole resistance in Entamoeba histolytica.
J. Antimicrob. Chemother.
40:833-840 |
| 30. | Saurina, G. R., and W. M. McCormack. 1997. Trichomoniasis in pregnancy. Sex. Transm. Dis. 24:361-362[Medline]. |
| 31. | Scully, B. E. 1988. Metronidazole. Med. Clin. North Am. 72:613-621[Medline]. |
| 32. |
Sobel, J. D.,
V. Nagappan, and P. Nyirjesy.
1999.
Metronidazole-resistant vaginal trichomoniasis an emerging problem.
N. Engl. J. Med.
341:292-293 |
| 33. | Thammapalerd, N., S. Tharavanij, and Y. Wattanaoon. 1993. Axenic cultivation of Entamoeba histolytica from liver abscess and its zymodeme. Southeast Asian J. Trop. Med. Public Health 24:480-483[Medline]. |
| 34. | Townson, S. M., H. Laqua, P. Upcroft, P. F. L. Boreham, and J. A. Upcroft. 1992. Induction of metronidazole and furazolidone resistance in Giardia. Trans. R. Soc. Trop. Med. Hyg. 86:521-522[CrossRef][Medline]. |
| 35. | Townson, S. M., J. A. Upcroft, and P. Upcroft. 1996. Characterisation and purification of pyruvate: ferredoxin oxidoreductase from Giardia duodenalis. Mol. Biochem. Parasitol. 97:183-193. |
| 36. |
Upcroft, J. A.,
R. W. Campbell,
K. Benakli,
P. Upcroft, and P. Vanelle.
1999.
Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and -resistant Giardia, Trichomonas and Entamoeba spp.
Antimicrob. Agents Chemother.
43:73-76 |
| 37. |
Upcroft, J. A.,
R. Mitchell,
N. Chen, and P. Upcroft.
1996.
Albendazole resistance in Giardia is correlated with cytoskeletal but not with a mutation at amino acid 200 in -tubulin.
Microb. Drug Resist.
2:303-308[Medline].
|
| 38. | Upcroft, J. A., P. F. L. Boreham, R. W. Campbell, R. W. Shepherd, and P. Upcroft. 1995. Biological and genetic analysis of a longitudinal collection of Giardia samples derived from humans. Acta Trop. 60:35-46[CrossRef][Medline]. |
| 39. | Upcroft, J. A., and P. Upcroft. 1993. Drug resistance and Giardia. Parasitol. Today 9:187-190. |
| 40. |
Upcroft, P., and J. A. Upcroft.
2001.
Drug targets and mechanisms of resistance in the anaerobic protozoa.
Clin. Microbiol. Rev.
14:150-164 |
| 41. | Viikki, M., E. Pukkala, P. Nieminen, and M. Hakama. 2000. Gynaecological infections as risk determinants of subsequent cervical neoplasia. Acta Oncol. 39:71-75[CrossRef][Medline]. |
| 42. | Voolmann, T., and P. F. L. Boreham. 1993. Metronidazole resistant Trichomonas vaginalis in Brisbane. Med. J. Aust. 159:490[Medline]. |
| 43. | Wachter, D. A., M. P. Joshi, and B. Rimal. 1999. Antibiotic dispensing by drug retailers in Kathmand, Nepal. Trop. Med. Int. Health 4:782-788[CrossRef][Medline]. |
| 44. | Warhurst, D. C. 1999. Drug resistance in Plasmodium falciparum malaria. Infection 27(Suppl. 2):S55-S58. |
| 45. |
Wassmann, C.,
A. Hellberg,
E. Tannich, and I. Bruchhaus.
1999.
Metronidazole resistance in the protozoan parasite Entamoeba histolytica is associated with increased expression of iron-containing superoxide dismutase and peroxiredoxin and decreased expression of ferredoxin 1 and flavin reductase.
J. Biol. Chem.
274:26051-26056 |
| 46. | Zalcberg, J., X. F. Hu, A. Slater, J. Parisot, S. El-Osta, P. Kantharidis, S. T. Chou, and J. D. Parkin. 2000. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis. 3:66-75[CrossRef][Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |